US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Apnimed

18.54

+0.31501.73%

Volume:69.00K

Turnover:1.28M

Market Cap:771.63M

PE:4.76

High:18.93

Open:18.18

Low:17.80

Close:18.22

52wk High:35.29

52wk Low:16.12

Shares:41.63M

Float Shares:12.00M

Volume Ratio:0.56

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):3.90

EPS(LYR):-23.7581

ROE:--

ROA:-36.94%

PB:-4.38

PE(LYR):-0.78

Loading ...

Overview Company News Filings

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apnimed Adopts New IPO-Era Bylaws with Advance Notice Rules for Shareholder Proposals

Apnimed Director Paul J. Sekhri Acquires $200,000 in Common Shares

Apnimed opens at $22.00, IPO priced at $16.00

NASDAQ Trade Halt Volatility Trading Pause at 11:49 Am

Stock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range

Sleep Apnea Pill Developer Apnimed Poised to Jump in Debut After Upsized IPO

Apnimed Upsized IPO Priced at Top of Expectations

NASDAQ Trade Halt Reason not Available at 04:00 Am

Correction: Apnimed Prices $192 Million IPO

MT Newswires Live

Apnimed Inc - Pricing of IPO of 12,000,000 Shares of Its Common Stock at a Price to Public of $16.00 Per Share.

THOMSON REUTERS

Apnimed Announces Pricing of Upsized Initial Public Offering

THOMSON REUTERS

Apnimed - AD109 Generally Well-tolerated in Phase 3 Trials with Common Adverse Events Dry Mouth, Insomnia, Nausea

THOMSON REUTERS

Apnimed Announces FDA Acceptance of New Drug Application for Ad109, an Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (osa)

THOMSON REUTERS

Apnimed - FDA Sets Pdufa Target Action Date of February 28, 2027 for AD109 Nda

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/APMD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APMD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","market":"US","secType":"STK","nameCN":"Apnimed","latestPrice":18.535,"timestamp":1791558539130,"preClose":18.22,"halted":0,"volume":68997,"delay":0,"changeRate":0.017288693743139478,"floatShares":12000000,"shares":41630779,"eps":3.898,"marketStatus":"Trading","change":0.315,"latestTime":"10-09 11:09:02 EDT","open":18.18,"high":18.93,"low":17.8,"amount":1278841.248789,"amplitude":0.06202,"askPrice":18.64,"askSize":136,"bidPrice":18.37,"bidSize":80,"shortable":3,"etf":0,"ttmEps":3.898,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"listingDate":1785470400000,"exchange":"NASDAQ","adjPreClose":18.22,"preHourTrading":{"tag":"盘前","latestPrice":17.41,"preClose":18.22,"latestTime":"08:11 EDT","volume":50,"amount":935.1000000000001,"timestamp":1791547915209,"change":-0.81,"changeRate":-0.044457,"amplitude":0.100988},"postHourTrading":{"tag":"盘后","latestPrice":18.22,"preClose":18.22,"latestTime":"19:30 EDT","volume":3622,"amount":66001.08,"timestamp":1791502204179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.56029},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","floatShares":12000000,"roa":"-36.94%","roe":"--","lyrEps":-23.758134,"volumeRatio":0.56029,"shares":41630779,"dividePrice":0,"high":18.93,"amplitude":0.06202,"preClose":18.22,"low":17.8,"week52Low":16.12,"pbRate":"-4.38","psRate":"6.70","week52High":35.29,"institutionHeld":0,"latestPrice":18.535,"committee":-0.259259,"eps":3.898,"divideRate":0,"volume":68997,"delay":0,"ttmEps":3.898,"open":18.18,"prevYearClose":16,"prevWeekClose":21.51,"prevMonthClose":21.91,"prevQuarterClose":21.91,"fiveDayClose":21.51,"twentyDayClose":26.23,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APMD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APMD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APMD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APMD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APMD","date":"2026-10-08","current":4.755003,"percent":0.617021,"low":-12.845073,"twenty":-11.854131,"median":-8.256435,"eighty":5.731189,"high":7.380306,"avg":-3.868979,"sd":8.129071,"marketCap":751019253},"quantilePoints":[{"date":"2026-08-07","current":-8.661063,"twenty":-8.320585,"median":-7.986942,"eighty":-7.766377,"marketCap":1110270342},{"date":"2026-08-14","current":-8.943759,"twenty":-8.664791,"median":-8.256435,"eighty":-7.766377,"marketCap":1146509438},{"date":"2026-08-21","current":-12.343549,"twenty":-9.895607,"median":-8.661063,"eighty":-7.942829,"marketCap":1582331874},{"date":"2026-08-28","current":-12.417048,"twenty":-11.890448,"median":-9.403529,"eighty":-8.185761,"marketCap":1591753815},{"date":"2026-09-04","current":-12.023611,"twenty":-12.049552,"median":-9.950282,"eighty":-8.269016,"marketCap":1541318719},{"date":"2026-09-11","current":-8.703457,"twenty":-12.127375,"median":-10.111822,"eighty":-8.343574,"marketCap":1115704877},{"date":"2026-09-18","current":7.153807,"twenty":-12.066846,"median":-9.872618,"eighty":-7.766377,"marketCap":1170241197},{"date":"2026-09-25","current":5.50469,"twenty":-12.02707,"median":-8.703457,"eighty":6.030983,"marketCap":900473749},{"date":"2026-10-02","current":5.736279,"twenty":-11.930224,"median":-8.524375,"eighty":5.874723,"marketCap":938357758},{"date":"2026-10-08","current":4.591059,"twenty":-11.854131,"median":-8.256435,"eighty":5.731189,"marketCap":751019253}],"updateTime":1791558542802},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APMD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656307836","title":"Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2656307836","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656307836?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:35","pubTimestamp":1785789300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Aug.  03, 2026  (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercializati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337925/0/en/Apnimed-Announces-Closing-of-Upsized-Initial-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","APMD","BK4082","OSA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656090593","title":"Apnimed Adopts New IPO-Era Bylaws with Advance Notice Rules for Shareholder Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2656090593","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656090593?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:03","pubTimestamp":1785787399,"startTime":"0","endTime":"0","summary":"Apnimed adopts new IPO-era bylaws with advance notice rules for shareholder proposalsApnimed adopted second amended and restated bylaws effective Aug. 3, 2026, tied to its initial public offering.The ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3LMVj0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656097513","title":"Apnimed Director Paul J. Sekhri Acquires $200,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2656097513","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656097513?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:01","pubTimestamp":1785787308,"startTime":"0","endTime":"0","summary":"Apnimed director Paul J. Sekhri acquires $200,000 in common sharesApnimed director Paul J. Sekhri reported buying 12,500 common shares at USD 16, lifting his direct holding to 12,500 shares.He also re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL5CHx8G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Apnimed Director Paul J. Sekhri Acquires $200,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656398107","title":"Apnimed opens at $22.00, IPO priced at $16.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2656398107","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656398107?lang=en_us&edition=fundamental","pubTime":"2026-08-01 00:15","pubTimestamp":1785514553,"startTime":"0","endTime":"0","summary":"Apnimed (APMD) priced 12M shares at $16.00. The deal size was increased to 12M shares from 10M shares of common stock and priced at the high-end of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apnimed-opens-at-22-00-ipo-priced-at-16-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apnimed-opens-at-22-00-ipo-priced-at-16-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRHC","IPOS","KCE","APMD","BK4127","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655607223","title":"NASDAQ Trade Halt Volatility Trading Pause at 11:49 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2655607223","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655607223?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:49","pubTimestamp":1785512983,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 11:49 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nAQN2MCM7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184287020","title":"Stock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range","url":"https://stock-news.laohu8.com/highlight/detail?id=1184287020","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184287020?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:46","pubTimestamp":1785512783,"startTime":"0","endTime":"0","summary":"Shares of Apnimed (APMD) surged 37.5% in intraday trading on Friday, as the clinical-stage biotech made a strong debut on the Nasdaq Global Select Market. The stock opened significantly higher than...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655601183","title":"Sleep Apnea Pill Developer Apnimed Poised to Jump in Debut After Upsized IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2655601183","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655601183?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:32","pubTimestamp":1785511920,"startTime":"0","endTime":"0","summary":"BUZZ-Sleep apnea pill developer Apnimed poised to jump in debut after upsized IPO** Late-stage biotech ApnimedAPMD.Oon track to jump in Nasdaq debut on Fri after above-target IPO** APMD shares recently indicated to open at $22 vs $16 offering price** Cambridge, Massachusetts-based firm late Thurs sold 12 mln shares for $192 mln raise** Co had marketed deal size of 10 mln shares at $14-$16** Its sole clinical product candidate, AD109 , is a once-daily pill taken at night to treat obstructive sleep apnea , a condition in which the airway repeatedly collapses during sleep, lowering oxygen levels and disrupting breathing** Morningside, Alpha Wave Ventures and Japanese pharma Shionogi & Co4507.Tare its largest shareholders, per the prospectus** BofA, Evercore, Cantor Fitzgerald and LifeSci Capital joint bookrunners on the IPO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL6N43X12X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","EVR","APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354798","title":"Apnimed Upsized IPO Priced at Top of Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655354798?lang=en_us&edition=fundamental","pubTime":"2026-07-31 17:46","pubTimestamp":1785491160,"startTime":"0","endTime":"0","summary":"Shares of Apnimed are set to make their trading debut Friday after the clinical-stage pharmaceutical company's upsized initial public offering was priced at the high end of expectations, raising $192 million.Apnimed late Thursday said it is selling 12 million shares at $16 each in the IPO, compared with prior plans to offer 10 million shares at between $14 and $16 apiece.Apnimed shares are due to begin trading later Friday on the Nasdaq Global Select Market under the symbol APMD.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","KCE","REDS","APMD","IPOS","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655949355","title":"NASDAQ Trade Halt Reason not Available at 04:00 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2655949355","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655949355?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:00","pubTimestamp":1785484802,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTREASON NOT AVAILABLE AT 04:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nAQN2MCJ82:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655353955","title":"Correction: Apnimed Prices $192 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2655353955","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655353955?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:32","pubTimestamp":1785483133,"startTime":"0","endTime":"0","summary":"(Correct company name in the first paragraph)Apnimed has priced its initial public offering of 12 million common shares at $16 per share, the drugmaker said late Thursday.Underwriters have been grante","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APMD","BK4127","IPOS","FRHC","REDS","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333927","title":"Apnimed Inc - Pricing of IPO of 12,000,000 Shares of Its Common Stock at a Price to Public of $16.00 Per Share.","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655333927?lang=en_us&edition=fundamental","pubTime":"2026-07-31 10:10","pubTimestamp":1785463803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUA3STF4F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333922","title":"Apnimed Announces Pricing of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333922","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655333922?lang=en_us&edition=fundamental","pubTime":"2026-07-31 10:10","pubTimestamp":1785463803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUA3STF4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651210870","title":"Apnimed - AD109 Generally Well-tolerated in Phase 3 Trials with Common Adverse Events Dry Mouth, Insomnia, Nausea","url":"https://stock-news.laohu8.com/highlight/detail?id=2651210870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651210870?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:00","pubTimestamp":1784030409,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA24M3K3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651108039","title":"Apnimed Announces FDA Acceptance of New Drug Application for Ad109, an Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (osa)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651108039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651108039?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:00","pubTimestamp":1784030409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA24M3K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651033108","title":"Apnimed - FDA Sets Pdufa Target Action Date of February 28, 2027 for AD109 Nda","url":"https://stock-news.laohu8.com/highlight/detail?id=2651033108","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651033108?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:00","pubTimestamp":1784030409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA24M3K3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APMD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}